Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
MAM-M82E3 | Mouse | Biotinylated Mouse MAdCAM-1 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
MAM-C82E3 | Cynomolgus | Biotinylated Cynomolgus MAdCAM-1 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
MAM-H52H4 | Human | Human MAdCAM-1 Protein, His Tag (MALS & SPR verified) | ![]() |
![]() ![]() |
![]() ![]() |
MAM-H8251 | Human | Biotinylated Human MAdCAM-1 Protein, Fc,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
MAM-H5253 | Human | Human MAdCAM-1 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Human MAdCAM-1, His Tag (Cat. No. MAM-H52H4) immobilized on CM5 Chip can bind Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) with an affinity constant of 0.227 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Vedolizumab | MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 | Approved | Millennium Pharmaceuticals Inc | 安吉优, Entyvio | EU | Pouchitis | Takeda Pharma A/S | 2014-05-20 | HIV Infections; Acquired Immunodeficiency Syndrome; Solid tumours; Inflammatory Bowel Diseases; Pediatric Crohn's disease; Pouchitis; Colitis; Celiac Disease; Cholangitis, Sclerosing; Pediatric ulcerative colitis; Colitis, Ulcerative; Urogenital Neoplasms; Crohn Disease; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ontamalimab | SHP-647; PF-00547659; PF-547659 | Pfizer Inc | Details |
This web search service is supported by Google Inc.